

ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression

Received: 27 May 2025

Accepted: 26 January 2026

Cite this article as: Shen, Y., Gupta, K., Tan-Wong, S.M. *et al.* ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression. *Nat Commun* (2026). <https://doi.org/10.1038/s41467-026-69169-7>

Yuqi Shen, Kinam Gupta, Sue Mei Tan-Wong, Sean Wen, Christopher A. Fisher, Liezel Tamon, Nicholas J. Proudfoot, Richard J. Gibbons & Douglas R. Higgs

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

If this paper is publishing under a Transparent Peer Review model then Peer Review reports will publish with the final article.

ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression

Yuqi Shen^{1,2}, Kinam Gupta³, Sue Mei Tan-Wong⁴, Sean Wen^{2,5}, Christopher A. Fisher², Liezel Tamon⁵, Nicholas J. Proudfoot⁴, Richard J. Gibbons^{1,2*}, Douglas R. Higgs^{1,3*}

1. Chinese Academy of Medical Sciences Oxford Institute (COI), Nuffield Department of Medicine, University of Oxford, Oxford, UK
2. Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), Radcliffe Department of Medicine, University of Oxford, Oxford, UK
3. Laboratory of Gene Regulation, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
4. Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
5. Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

*Corresponding authors: doug.higgs@imm.ox.ac.uk; richard.gibbons@ndcls.ox.ac.uk

Abstract

Germline mutations in the chromatin remodelling protein ATRX cause a severe developmental disorder associated with α -thalassemia. In addition, *ATRX* is amongst the twenty genes most frequently mutated in cancer. How *ATRX* mutations alter gene expression remains unclear. Using the α -globin locus as a model, here we show that ATRX deficiency downregulates α -globin in a subset of cells exhibiting DNA damage. A G-rich repeat at the α -globin locus serves as a potential site of G-quadruplex formation and DNA damage. ATRX binds this repeat co-transcriptionally, and its loss increases R-loop accumulation at this site, leading to local DNA damage and transcriptional disruption *in cis*. Deletion of this repeat abolishes this effect, while targeted DNA damage reinstates it. These findings reveal a mechanism linking ATRX's role in genome stability to transcriptional regulation and uncover a molecular basis of human genetic disease mediated via a distal G-rich repeat.

Introduction

The *ATRX* gene was first identified because when mutated it causes a specific, severe form of syndromic intellectual disability associated with alpha-thalassaemia: so-called alpha-thalassaemia X-linked intellectual disability (ATR-X) syndrome¹. *ATRX* thus plays a key role in normal development², and it is also one of the twenty genes most frequently mutated in cancer^{3–5}. *ATRX* is a highly conserved SWI/SNF chromatin remodelling protein, which forms a multiprotein complex with the histone variant H3.3 and its chaperone DAXX to maintain chromatin organisation^{6–9}. *ATRX* plays a part in many nuclear processes including DNA replication, transcription, DNA damage and DNA repair^{10–17}. Although previous studies have mapped *ATRX* binding to heterochromatin, CpG islands, and active regulatory elements^{18–22}, the precise mechanisms by which *ATRX* regulates gene expression remain unclear. Notably, *ATRX* selectively affects human alpha-globin (α -globin), but not beta-globin (β -globin) expression during erythropoiesis -- a process requiring coordinated expression of α - and β -globin genes to form haemoglobin heterotetramers ($\alpha_2\beta_2$), providing a tractable model to explore its regulatory function.

In marked contrast to the β -globin cluster, the human α -globin cluster lies within an early replicating, GC-rich, gene dense, sub-telomeric region of chromosome 16. The human α -globin genes are associated with prominent unmethylated CpG islands^{23,24} and are embedded within a region of the genome containing a high density of repeat sequences including several GC-rich variable number tandem repeats (VNTRs) (**Fig. 1a**). In ATR-X syndrome, mutations in *ATRX* downregulate gene expression at the human α -globin locus, with the α -like globin gene *HBM* being most affected, followed by α -globin genes *HBA2* and *HBA1*¹⁹, suggesting a unique mechanism of gene regulation.

In this study, we investigate how *ATRX* loss leads to α -thalassaemia, a key disease phenotype of ATR-X syndrome, by elucidating the mechanisms that link *ATRX*'s gene regulatory functions to human disease. Here we show that dysregulation of α -globin expression in the absence of *ATRX* depends on a G-rich VNTR within the human α -globin locus. Loss of *ATRX* promotes G-quadruplex (G4) and R-loop formation at this site,

resulting in DNA damage and distance-dependent disruption of gene expression. Removal of this VNTR abolished the gene downregulation caused by ATRX loss and inducing DNA damage at this site restored the effect. Together, our findings uncover a systematic mechanism of ATRX-mediated gene regulation, highlighting its role in orchestrating genome stability and transcription regulation. In addition, by directly linking molecular dysfunction at tandem repeats to human pathology, our work reveals a pathogenic mechanism underlying human genetic disease, underscoring the clinical significance of genome stability and chromatin dynamics at repetitive loci.

Results

ATRX loss perturbs α -globin expression in a subset of cells

To unravel the underlying mechanism by which ATRX regulates α -globin expression, we established an ATRX-deficient model by inducing a knockout (KO) of *ATRX*, using CRISPR/Cas9, in CD34+ haematopoietic stem and progenitor cells (HSPCs) from healthy male donors. Cells were electroporated with ribonucleoprotein (RNP, Cas9 protein complexed with guide RNA) targeting either *ATRX*, or as a control, the safe-harbour locus *AAVS1*. These CD34+ cells were then differentiated into erythroid cells using a three-phase differentiation system²⁵ for genotype and phenotype analysis (**Fig. 1b**). Genotype analysis detected an average of 84.7% indels and 72% of knockout (out-of-frame) effect (**Supplementary Fig. 1a**), and the abolishment of ATRX was confirmed at the protein level (**Fig. 1c**). Consistent with ATRX's role in replication^{10,14,15}, ATRX KO cells showed slightly slower cell proliferation (**Supplementary Fig. 1b**). Phenotypically, ATRX KO cells demonstrated normal erythroid differentiation (**Supplementary Fig. 1c**) and cellular morphology (**Supplementary Fig. 1d**). Haemoglobin analysis revealed a similar pattern to the controls, with dominant adult haemoglobin A (HbA) expression and minor fetal haemoglobin (HbF) expression (**Supplementary Fig. 1e**). As in the peripheral blood of many patients with ATR-X syndrome, ATRX KO cells only showed a very mild (non-significant) reduction in *HBM* expression (**Fig. 1d**) and no erythroid cells with haemoglobin H (HbH, β_4) inclusions were found².

The absence of an α -thalassemia phenotype in ATRX KO cells may be due to the ATRX defect affecting only a small subset of cells, which is often obscured in a bulk population analysis. To address this, early erythroid progenitors (EEP) cells were sorted (**Supplementary Fig. 1f**) and plated for a colony-forming unit (CFU) assay, which allowed us to determine the genotype and the pattern of gene expression in individual erythroid colonies. ATRX KO sample showed similar haematopoietic progenitor frequencies (**Supplementary Fig. 1g**) and colony-forming capacity (**Supplementary Fig. 1h-i**) as the AAVS1 control. Single burst-forming unit-erythroid (BFU-E) colonies were then manually picked and analysed for their genotype and gene expression. A total of 96 BFU-E colonies from the AAVS1 sample and 351 colonies from the ATRX KO sample were analysed. Out of the 351 collected colonies, 240 (68.38%) had frameshift (FS) indels (**Fig. 1e**). Fifty AAVS1 “edited” colonies and 190 colonies from the ATRX sample harbouring ATRX frameshift (FS) indels were randomly selected for Biomark gene expression analysis. This showed reduced ATRX expression in most ATRX_FS colonies, however, only a subset showed decreased HBM and HBA expression (**Fig. 1f**). As expected from previous work¹⁹, HBM was more affected than HBA (**Fig. 1g**). Together, these results indicate that as in the peripheral blood of ATRX patients²⁰, loss of ATRX affects gene expression at the α -globin locus in only a subset of cells, and HBM is more affected than HBA.

scRNA-seq links the gene perturbation to DNA damage response

To uncover the associated molecular signatures in the affected cells and elucidate ATRX's regulatory mechanisms, we next performed single-cell RNA sequencing (scRNA-seq) on AAVS1 and ATRX KO cells. Characterisation during erythroid differentiation identified day 13 as optimal for single-cell analysis, in that ATRX KO cells showed pronounced *HBM* downregulation with a 77% knockout efficiency (**Supplementary Fig. 2a-c**). Accordingly, single day 13 nucleated erythroid cells were sorted for Smart-seq2 analysis (**Supplementary Fig. 2d**). After quality filtering and identification of highly variable genes (HVGs), principal component analysis (PCA) and t-distributed stochastic neighbour embedding (t-SNE) were performed. Both analyses indicated a closely overlapping distribution pattern between ATRX KO cells and the controls (**Fig. 2a, Supplementary**

Fig. 2e). Differential gene expression analysis identified only 53 differentially expressed genes (DEGs) that were significantly downregulated, including *HBM*, and 18 upregulated genes (**Fig. 2b**, full list provided in **Supplementary Data 1**).

Gene Ontology (GO) analysis of these DEGs highlighted pathways related to cell cycle, cell division, and erythrocyte function (**Supplementary Fig. 2f**), consistent with ATRX's roles in facilitating DNA replication^{10,14,15} and the observation of slower proliferation of ATRX KO cells in culture (**Supplementary Fig. 2a**). Of interest, *RNF168*, a key DNA damage response regulator, was significantly upregulated in ATRX KO cells (**Fig. 2b-c**), suggesting increased DNA damage in the absence of ATRX. The MRN-ATM- γ H2AX-RNF168 pathway is essential for DNA damage response and repair²⁶. ATRX has previously been shown to interact with the MRN complex to overcome replication stress and facilitate DNA repair¹⁴. To assess DNA damage in ATRX KO cells, we performed immunofluorescence staining for phosphorylated H2AX (γ H2AX) and observed an increased number and intensity of γ H2AX foci compared to the controls, indicating elevated DNA damage following ATRX loss (**Fig. 2d**).

To look into the transcriptomic signature of the affected subpopulation, cells were categorised based on globin gene expression. As a group, the ATRX KO sample showed similar levels of α -globin (*HBA*), β -globin (*HBB*), and γ -globin (*HBG*) expression to AAVS1 control but significantly reduced α -like-globin *HBM* expression (**Fig. 2e**). However, scatter plots revealed a subpopulation of ATRX KO cells at quiescent G1 phase with low α -(like)-globin expression (*HBM* and *HBA*) but normal *HBB* expression (**Fig. 2f**, **Supplementary Fig. 3a-b**), indicating this subpopulation of cells exhibited α -thalassemia. This enables us to group cells into HBM^{low} , HBM^{mid} and HBM^{high} based on their *HBM* expression ($HBM^{\text{low}} < 2.5$, $HBM^{\text{high}} > 7$) (**Supplementary Fig. 3c**), with HBM^{low} exhibiting more separated clustering in the tSNE plot (**Supplementary Fig. 3d**). DEG and GO analysis between HBM^{high} and HBM^{low} cells (**Supplementary Fig. 3e**) identified 56 downregulated pathways exclusively in the HBM^{low} ATRX KO cells (**Supplementary Fig. 3f**, **Supplementary Data 2**). The analysis also indicated 5 upregulated pathways exclusively in the affected HBM^{low} ATRX KO cells (**Supplementary Data 2**), including mitochondrial

dysfunction, cell responses, and importantly, histone H2A ubiquitination pathways (**Fig. 2g**). Interestingly, histone H2A is the primary histone substrate of RNF168 and closely associated with transcriptional silencing²⁷. To validate whether H2A ubiquitination is dysregulated in ATRX KO cells, immunofluorescence staining for ubiquitinated H2A (H2Aub) was performed. A subset of ATRX KO cells exhibited increased H2Aub intensity, indicating activation of the DNA damage response pathway (**Fig. 2h**). Consistently, UIMC1 (RAP80), a ubiquitin-binding protein that recognises ubiquitinated histones at DNA damage sites²⁸, was significantly upregulated in the affected ATRX KO HBM^{low} subpopulation (**Fig. 2i, Supplementary Fig. 3g**). Collectively, these findings suggest ATRX loss leads to increased DNA damage and enhanced RNF168-mediated H2A ubiquitination, which may contribute to the repression of genes lying within or adjacent to regions of DNA damage.

ATRX regulates gene expression at the α -globin locus via a G-rich VNTR

A potential site of DNA damage at the human α -globin locus is a highly repetitive VNTR region with 96% GC content, located within the second intron of the pseudogene *HBZP1*. This is located approximately 1 kb upstream of *HBM*, 8 kb upstream of *HBA2*, 12 kb upstream of *HBA1* and is referred to as the pseudo-zeta ($\psi\zeta$) VNTR (**Fig. 1a**). This VNTR comprises highly G-rich repeats (CGCGGGGCGGGG)_n that can form G4 structures *in vitro*^{19,29}, making it a prime candidate for causing DNA damage at the α -globin locus in the absence of ATRX. Of importance, we have previously shown that the size of $\psi\zeta$ VNTR positively correlates with the degree of α -globin downregulation in patients with ATR-X syndrome¹⁹. This led us to hypothesise that the $\psi\zeta$ VNTR acts as a transcriptional modulator of human α -globin expression regulated via ATRX. Of interest, this VNTR is absent in the mouse genome and ATRX deficiency in mouse models of ATRX syndrome do not have α -thalassaemia³⁰.

Using a well-established human model to study erythropoiesis (HUDEP-2 erythroid progenitor cell line), we tracked ATRX binding at the $\psi\zeta$ VNTR during erythroid differentiation. ATRX ChIP-seq demonstrated that ATRX starts to bind at the $\psi\zeta$ VNTR on

day 4 of differentiation coincident with the onset of transcription of the zeta (ζ) pseudogene *HBZP1* and α -(like)-globin gene (**Fig. 3a-c**). This binding pattern, correlated with transcriptional activation, aligns with prior evidence of ATRX associating with G-rich sequences when they are transcribed³¹. To study the influence of the $\psi\zeta$ VNTR on α -globin gene expression, we first generated an inducible ATRX degron system in HUDEP-2 cells (**Fig. 3d**) and subsequently knocked out the $\psi\zeta$ VNTR. Characterisation of the ATRX degron cell line indicated normal erythroid differentiation, even under dTAG-13 treatment (**Supplementary Fig. 4a-b**). dTAG-13 induced rapid and potent degradation of ATRX (**Fig. 3e, Supplementary Fig. 4c**). As expected, this was associated with a significantly reduced level of *HBM* expression and slightly decreased *HBA* expression (**Fig. 3f, Supplementary Fig. 4d**), faithfully mimicking the mild α -thalassaemia phenotype seen in ATR-X syndrome. To test whether the degradation of ATRX downregulates α -globin expression via an effect on the $\psi\zeta$ VNTR, we next generated a HUDEP-2 cell line in which the $\psi\zeta$ VNTR was deleted from both alleles via CRISPR-Cas9 (**Supplementary Fig. 5a**) and repeated the dTAG experiment. The VNTR KO line showed normal erythroid differentiation (**Supplementary Fig. 5b-c**), and ATRX can be potently degraded by dTAG-13 (**Fig. 3e**). Interestingly, in striking contrast to the previous experiment, when the $\psi\zeta$ VNTR was removed, *HBM* was no longer downregulated in the absence of ATRX (**Fig. 3f**), showing that downregulation of *HBM* expression in the absence of ATRX is mediated via the G-rich $\psi\zeta$ VNTR.

G4s, R-loops, and DNA damage at G-rich VNTRs drives gene dysregulation

The $\psi\zeta$ VNTR is predicted to form highly stable G4 structures (G4Hunter^{32,33} score > 2) (**Supplementary Fig. 6a**). Treating cells with G4 stabilisers during day 6 to 8 of differentiation revealed that CX-5461 specifically downregulated *HBM* expression to levels comparable to that seen when ATRX is absent, but had little effect on the beta-globin genes (**Fig. 4a, Supplementary Fig. 6b**). A similar downregulation of gene expression was observed at another ATRX target gene, *NME4* (**Supplementary Fig. 6b**), which also contains a G-rich VNTR predicted to form a highly stable G4 structure (G4Hunter score > 2) (**Supplementary Fig. 6c**). To assess whether this represents a

broader phenomenon, we examined the 71 genes dysregulated in CD34 ATRX knockout cells for the presence of GC-rich repetitive elements. Notably, 45 of 71 genes (63.4%) contained GC-rich tandem or low-complexity repeats (**Supplementary Data 1**), which is significantly higher than the genome-wide background rate of such repeats (23.3%, analysis based on the UCSC RepeatMasker track, $p < 1 \times 10^{-15}$; one-tailed binomial test). This suggests a general mechanism by which the absence of ATRX perturbs the expression of genes associated with such sequences. Consistent with this, when the $\psi\zeta$ VNTR was deleted, CX-5461 no longer had effect on *HBM* expression (**Fig. 4a**) but retained its effect on *NME4* expression (**Supplementary Fig. 6b**), implicating the formation of G4 structures at the $\psi\zeta$ VNTR in *HBM* regulation.

It has previously been shown that ATRX binds to known G4 structures when they are transcribed and that accumulate R-loops which stabilise such structures^{31,34}. In line with this, ATRX-deficient cells displayed a genome-wide increase in R-loops (**Fig. 4b**). DNA:RNA IP (DRIP)-qPCR further revealed significantly elevated R-loop formation at the $\psi\zeta$ VNTR locus in the absence of ATRX (**Fig. 4c**). Interestingly, overexpression of RNase H in ATRX-deficient cells partially restored *HBM* downregulation (**Fig. 4d**), supporting a functional role for R-loops in regulating *HBM* transcription. Accumulated G4 structures and R-loops are known to cause replicative stress and DNA damage, leading to perturbed chromatin and local transcriptional silencing^{35–37}. Hence, we proposed that ATRX depletion induces the formation of unusual secondary structures at the $\psi\zeta$ VNTR, which triggers DNA damage and downregulates the nearby α -(like)-globin genes (*HBM* and *HBA*).

To test whether DNA damage alone could drive *HBM* dysregulation, we introduced local DNA double-strand breaks (DSBs) upstream of *HBM* via CRISPR/Cas9 targeting in the region where the $\psi\zeta$ VNTR had been deleted (VNTR KO Cells) (**Fig. 4e**). Interestingly, this artificially induced DNA damage led to marked downregulation of *HBM* and, to a lesser extent, *HBA* expression (**Fig. 4f**). This suggests that downregulation of *HBM* and *HBA* gene expression and the consequent alpha-thalassaemia occurs *in cis* as a result of DNA damage at the $\psi\zeta$ VNTR. It has been previously reported that transcription is

highly repressed at sites adjacent to DSBs, and that this repression decreases upon movement away from the lesion^{38,39}, as shown at the α -globin locus ($HBM > HBA2 > HBA1$)¹⁹. The mechanism appears to be complex⁴⁰, but the α -globin locus model presented here offers the opportunity to solve this in detail.

Discussion

ATRX has long been recognised as an important genomic guardian, with its loss associated with increased genomic instability and transcriptional dysregulation. Previous studies have established that ATRX deficiency leads to DNA replication defects^{10,14,41} and promotes the accumulation of non-canonical DNA structures, such as G-quadruplexes (G4s)^{29,35,42,43} and R-loops^{31,34}. However, these investigations have largely examined individual aspects of ATRX function in isolation, the molecular mechanisms connecting ATRX's chromatin remodelling activity to gene regulation therefore remain incompletely resolved. In this study, we leverage the α -globin gene cluster, a well-characterised target of ATRX, to establish an integrated model that unifies these mechanistic elements. Through this, we demonstrate how ATRX orchestrates non-canonical genomic structures, genome stability, and transcriptional output within a physiological context, thereby elucidating how ATRX deficiency leads to transcriptional dysregulation.

We show that loss of ATRX downregulates α -globin expression in only a subset of cells exhibiting elevated levels of DNA damage. Using an inducible ATRX degron system, we found that ATRX normally binds to a G-rich VNTR when the region is transcribed, and prevents or resolves the formation of R-loops. In the absence of ATRX, persistent R-loops accumulate at the transcribed VNTR, triggering DNA damage that consequently disrupts gene expression *in cis* (**Fig. 5**). Although G4 structures and R-loops may also form at other G-rich regions within the α -globin locus including the ζ -VNTR⁴⁴, the close proximity and genetic linkage of α -thalassaemia to the $\psi\zeta$ VNTR¹⁹ make $\psi\zeta$ VNTR the leading candidate for the effect proposed here. Of note, VNTRs are inherently variable in size, and such variation is likely to influence their propensity to form G4s and R-loops, which

in turn correlates with gene expression, as reported in ATR-X syndrome¹⁹. Assessing the impact of VNTR length on R-loop formation and chromatin dynamics in appropriate model systems would provide valuable mechanistic insight.¹⁹

While this mechanism is exemplified at α -globin, ATRX binds G-rich regions genome-wide (see examples in **Supplementary Data 1**), many of which are actively transcribed and prone to forming G4s and R-loops^{19,35,42,45}. Our findings therefore suggest that ATRX-dependent suppression of G4s and R-loops associated with actively transcribed regions is likely to be a general mechanism by which gene expression is maintained without interruption from the secondary consequences of unresolved G4 DNA structures. Disruption of this pathway of maintaining genome integrity may help explain aspects of the developmental defects observed in ATR-X syndrome and raise the possibility that similar processes could contribute to other phenotypes associated with ATRX mutations in ageing and cancer, where genomic instability and epigenetic deregulation are hallmarks of disease progression.

Consistent with ATRX's role in DNA replication^{10,14,15,41}, we observed that ATRX-deficient erythroid cells exhibit upregulated DNA damage and activated DNA damage response pathways (**Fig. 2d, 2g-i**). ATRX has been shown to interact with the MCM helicase complex, a key component of the replication machinery³⁵. Direct visualisation study revealed that G4s form immediately behind the MCM helicase at replication forks, impeding DNA synthesis and inducing replicative stress⁴⁶. These findings suggest that ATRX may collaborate with MCM to resolve transient G4 structures during replication. In support of this, Teng *et al.* have shown that the helicase domain of ATRX is required to protect cells from G4-induced replicative stress³⁵. Loss of ATRX compromises this protective mechanism, leading to G4 accumulation, fork stalling, replication stress, and DNA damage.

ATRX also suppresses aberrant nucleic acid structures during transcription. G-rich DNA regions are particularly prone to forming G4s and R-loops during transcription, which may interfere with transcription and replication. ATRX is enriched at such transcribed G-rich

loci, where its loss results in increased G4 and R-loop accumulation^{31,42}. Overexpression of RNase H in ATRX-deficient cells partially rescued *HBM* downregulation (**Fig. 4d**), suggesting that ATRX modulates R-loops and G4 structures through at least partially independent mechanisms. Given the high GC content (96%) of the $\psi\zeta$ VNTR, G4 formation likely occurs intrinsically and both G4 and R-loop formation are enhanced during transcription⁴⁷ in ATRX-deficient cells, thereby compromising genome stability. Recent reports also indicate a role of R-loops in facilitating DNA damage repair around DSBs, independent of sequence composition^{48,49}. Although R-loop formation at the α -globin locus is primarily driven by transcriptional activity and the GC richness, it remains an open question whether ongoing DNA damage further promotes R-loop accumulation. Investigating this potential feedback mechanism represents an important direction for future research.

Persistent G4 and R-loop structures may lead to replication-transcription collisions, ultimately resulting in DNA damage and activating DNA damage response pathways. Among the two primary DNA damage response kinases (ATM and ATR) ATM appears to play a more dominant role in responding to ATRX loss-induced damage. In the *Atrx*-null mouse embryonic brain, phosphorylated ATM is elevated while ATR levels remain unchanged⁵⁰. ATM signalling pathway is consistently activated in ATRX-deficient cells^{15,22,51}. In addition, ATRX promotes the recovery from replication stress by interacting with the MRN complex^{10,14}, a sensor of DSB that activates ATM⁵². Activation of this pathway leads to phosphorylation of ATM and downstream targets such as RNF168²⁶, a ubiquitin ligase that marks damaged chromatin by ubiquitinating histone H2A, which could be recognised by UIMC1 (RAP80)²⁸ thereby recruiting DNA repair proteins such as BRCA1 and 53BP1. Consistent with this pathway, we observed upregulation of *RNF168*, increased H2A ubiquitination, and elevated *UIMC1* expression in ATRX-deficient cells (**Fig. 2c, 2g-i**).

Importantly, this pathway does not merely facilitate DNA repair but also has direct impact on gene expression. Increased RNF168 recruitment and histone ubiquitination have been observed at DNA damage and G4 sites, and this DNA damage response-related ubiquitin

signalling pathway is frequently altered in cancers with aberrant gene expression^{53,54}. Ubiquitination at sites of damage has been linked to transcriptional silencing of nearby genes³⁹. Thus, activation of this pathway may contribute to gene repression at loci like α -globin in the context of ATRX deficiency. In addition, the histone variant macroH2A1 is one important factor in ATM-dependent DNA damage response. Both variants, macroH2A1.1 and macroH2A1.2, are recruited to DNA damage sites and promote local chromatin condensation^{55,56}. Importantly, macroH2A1.2 has been shown to be an epigenetic link between ATRX loss and DNA damage response at sites of recurrent replication stress^{57,58}, and macroH2A1 deposition at α -globin has been shown to be involved in ATRX-mediated α -globin regulation⁵⁹. The H2A ubiquitination and macroH2A1 deposition⁶³ might be complementary pathways in α -globin regulation, particularly both are associated with DNA damage responses and repressive chromatin states⁶⁰. Further study is needed to fully elucidate whether these two pathways act synergistically to regulate gene expression at damaged genomic loci.

As shown here, ATRX deficiency exerts these effects on only a subset of cells, suggesting that the consequences of ATRX loss accumulate in a stochastic and progressive manner. This is supported by the BFU-E colony assays in which only a fraction of colonies displayed gene downregulation (**Fig. 1f**), indicating that impairments in this subpopulation arise cumulatively during otherwise normal erythroid differentiation. Specifically, only cells that accumulate unresolved G4s/R-loops and replication stress are to be affected. The likelihood of a replication or transcription fork encountering these structures during a dynamic process introduces a stochastic element to the effect. Notably, ATRX is not the sole factor capable of destabilising G4s and R-loops; other helicases, such as FANCD1 DNA helicase, RecQ helicases, and DDX5^{49,64,65}, can also resolve these structures to release the cells from stress^{46,61,62}. Therefore, the affected subpopulation likely represents those in which G4s and R-loops persist because ATRX is absent and other complementary helicases fail to resolve these structures in time. With successive rounds of cell division and differentiation, these unresolved structures are predicted to accumulate, causing progressive DNA and chromatin impairment, ultimately suppressing gene expression. The stochastic nature of this phenomenon presents a technical

challenge for detecting α -globin locus-specific DNA damage and chromatin changes. A more robust model that exhibits a stronger and more consistent phenotype would be necessary to explore these aspects further, which we identify as an important avenue for future research. Likewise, assessing VNTR length heterogeneity at the single-cell level would help reveal whether the affected subset of cells carries longer repeats during differentiation. Although determining VNTR length in individual cells or single BFU-E colonies remains technically challenging, it represents another direction for future investigation.

Cell-cycle analysis revealed that the affected cells were predominantly in the G1 phase (**Supplementary Fig. 3b**). It is known that unrepaired DNA damage from G2/M phases is resolved during G1 through 53BP1 nuclear bodies, which often localize at chromosomal fragile sites⁶³. ATRX has been reported to colocalize with 53BP1 nuclear bodies in G1 to facilitate the repair of these fragile regions⁸. In our single-cell transcriptomic data, *TP53BP1* expression was modestly increased in ATRX KO cells, though not significantly, supporting a potential link between ATRX loss and G1-phase repair activity. Collectively, these data suggest that ATRX-deficient cells accumulate DNA damage at fragile sites that require G1-phase repair, resulting in the observed enrichment of cells in this phase.

In summary, our findings highlight the interconnected role of ATRX at G-rich loci in safeguarding genome stability and maintaining transcriptional fidelity, providing a coherent mechanism linking ATRX deficiency to human disease. The working model presented here not only bridges a key mechanistic gap in understanding ATRX function but also implicates clinical relevance. This mechanism accounts for several previously unexplained observations in ATR-X syndrome: the mild α -thalassemia in ATR-X syndrome (affecting only a subset of cells), the phenotypic heterogeneity among patients (distance- and VNTR size-dependent gene dysregulation) observed in patients¹⁹, and the absence of α -thalassemia in ATRX-deficient mouse models which do not harbour the $\psi\zeta$ VNTR³⁰. Together, these findings uncover a pathogenic mechanism of perturbed gene expression in ATR-X syndrome mediated by a distal VNTR. More broadly, they demonstrate how subtle underlying perturbations can lead to profound disease consequences.

Methods

CD34+ cell culture and differentiation

The CD34+ cells were separated from healthy adult peripheral blood leucocyte cones purchased from the National Health Service Blood and Transplant (NHSBT), UK. Ethical approval was granted by the Wales Research Ethics Committee (REC5) (13/WA/0371). The mononuclear cells were isolated using Histopaque-1077 (Sigma, Cat No H8889), and CD34+ cells were purified using Human CD34+ Microbead kit (Miltenyi Biotec, Cat No 130-046-702) following the manufacturer's instruction and the purity was confirmed by FACS. The CD34+ cells were cultured in StemSpan SFEM II media (StemCell Technologies, Cat No 9655) supplemented with 100 ng/mL SCF (PeproTech, Cat No 300-07), 100 ng/mL TPO (PeproTech, Cat No 300-18), 100 ng/mL Flt3L (PeproTech, Cat No 300-19) and 1x Penicillin/Streptomycin (P/S, Gibco, Cat No 15070063) for 24 hours at 37°C with 5% CO₂ incubation prior to electroporation. After electroporation, the cells were recovered in the same media without P/S for 24 hours before starting erythroid differentiation.

CD34+ cells were differentiated along the erythroid lineage using a previously described three-phase liquid culture system²⁵, requiring a base media Iscove's Modified Dulbecco's Medium (IMDM) (Gibco, Cat No 31980022) containing 3% Solvent/Detergent pooled Human AB plasma (NHSBT), 10 µg/mL human insulin (Merck, Cat No I9278), 3 U/mL heparin (Merck, Cat No H3149), 3 U/mL erythropoietin (EPO, Oxford University Hospital (OUH) pharmacy), 200 µg/mL iron saturated human holo-transferrin (Bio-Techne, Cat No 2914-HT), 2% (v/v) fetal bovine serum (FBS) and 1x P/S. In phase I (day 0 to day 7), 1 ng/mL IL3 (PeproTech, Cat No 200-03) and 10 ng/mL SCF were added. In phase II (day 7 to day 11), the IL3 was removed and only 10 ng/mL SCF was supplemented. In phase III (post day 11), only 300 µg/mL holo-transferrin was added. The media was changed every two days to maintain cell concentration around 1-2 x 10⁵ cells/mL in phase I and phase II, 0.5-1 x 10⁶ cells/mL in phase III.

CRISPR/Cas9 knocking out experiment in CD34+ cells

Given that ATRX is located on the chromosome X and ATR-X syndrome only affects males, donor gender was confirmed by checking the *SRY* gene on chromosome Y. Only CD34+ cells derived from the male donors were used for CRISPR experiment to achieve efficient ATRX knockout given the *ATRX* gene is located on chromosome X. $1-3 \times 10^5$ of CD34+ cells were transfected with RNPs (3.2 μ g sgRNA (synthesised by Synthego) + 6 μ g SpCas9 nuclease (IDT)) using Amaza P3 Primary cell 4D-Nucleofector X Kit (Lonza, Cat No V4XP-3032) and 4D-Nucleofector X Unit device (Lonza). Guide RNA sequences are listed in Supplementary Table 1. Cells were recovered in pre-warmed antibiotic-free SFEM II complete media right after the electroporation for 24 hours before the initiation of differentiation or cell sorting. ATRX knockout efficiency was assessed by Sanger sequencing of the targeted region using primers listed in Supplementary Table 1, followed by Synthego Inference of CRISPR Edits (ICE) analysis.

Colony forming unit assay

CFU assay was performed following the technical manual for Human CFU Assays Using MethoCult (STEMCELL Technologies, Cat No H4435). Single-cell suspensions were prepared and diluted in Iscove's MDM supplemented with 2% FBS medium (STEMCELL Technologies, Cat No 07700) and then mixed into enriched MethoCult (STEMCELL Technologies, Cat No H4435) to allow progenitor cells to expand and differentiate into colonies under incubation at 37°C with 5% CO₂. After 14-16 days of culture, colonies were examined and scored based on their morphology. Then the single individual BFU-E colonies were manually picked under a light inverted EVOS XL Imaging System (ThermoFisher Scientific, Cat No AME3300) and transferred into tubes containing cold PBS. Each collected colony sample was subsequently divided into two aliquots - one for genotyping after whole genome amplification and the other for gene expression analysis using the Fluidigm Biomark system.

Analysis of single BFU-E colonies

Genomic DNA from single BFU-E colonies was amplified directly from cell lysate using Illustra Single Cell GenomiPhi DNA Amplification Kit (GE Healthcare, Cat No 25-6600-30) following the manufacturer's instructions. Then PCR amplification of CRISPR target

regions and subsequent Sanger sequencing were conducted using the purified DNA to determine their genotype.

For gene expression analysis, samples were mixed with 2x Reaction Mix containing Superase-In and cDNA was pre-amplified by adding 0.2x Taqman assay mix and RT/Taq mix (from Superscript III One Step Kit, ThermoFisher, Cat No 12574026). The amplification was carried out on a Bio-Rad T100 Thermal Cycler under the following conditions: 50°C for 15 minutes, 95°C for 2 minutes, followed by 20 cycles of 95°C for 15 seconds and 60°C for 4 minutes. The resulting cDNA was diluted with 4x vol TE buffer and stored at -20°C for up to 3 months. Then the diluted cDNA and Taqman Assays were loaded onto an IFC chip for gene expression analysis as per protocols provided on the Fluidigm website. Data analysis was finished using the built-in software, adhering to the “Real-Time PCR Analysis” guidelines from Fluidigm. Colonies with undetected reference genes were excluded from further analysis. For gene expression analysis of *ATRX*, *HBA* and *HBM* in individual BFU-E colonies, expression values were normalised to the mean of reference genes (*RPL13A*, *RPS18*, *ACTB* and *GAPDH*), and a uniform cutoff of 2 was applied to relative expression values during plotting to exclude outlier values.

Cellular morphological analysis - Wright's stain of cytopsin

1×10^5 cells were resuspended in 200 μL of PBS, spun (400 rpm for 5 mins) onto a glass slide in a Cytospin 4 Centrifuge (ThermoFisher). The slides were air-dried, stained with modified Wright's Stain using Hemateck slide strainer and mounted in DPX (Sigma, Cat No 06522). Cytopsin were imaged using an Olympus BX 60 microscope.

Flow cytometry

Cells were washed and resuspended in 100 μL of FACS buffer (1x PBS supplemented with 2% FBS and 2 mM EDTA) prior to staining with a panel of fluorophore-conjugated antibodies at 4°C for 30 min. Following antibody staining, the cells were washed and resuspended in FACS buffer containing Hoechst-33258 for live/dead cell analysis. FACS analysis was done on an Attune NxT analyser (ThermoFisher). Gating was set using fluorescence-minus-one (FMO) and unstained controls. Analysis was performed using

FlowJo software. The details of the FACS panels and flow cytometry antibodies are provided in Supplementary Table 2.

Iso-electric focusing for haemoglobin analysis

Approximately 5×10^5 cultured erythroblasts were lysed in haemoglobin elution solution, and the haemoglobin was analysed using an iso-electric focusing kit (RESOLVE Haemoglobin kit, PerkinElmer, USA) on a water-cooled horizontal electrophoresis rig (GE Healthcare) according to the manufacturer's instructions. Following electrophoresis, the gels were fixed in 10% trichloroacetic acid and stained using the JB-2 staining system (Perkin Elmer, USA) as per the manufacturer's guidelines.

HUDEP-2 cell culture and differentiation

Wildtype HUDEP-2 cells were obtained from the Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Japan⁶⁴. During the expansion phase, cells were cultured in StemSpan SFEM medium (STEMCELL Technologies, Cat No 09650) supplemented with 50 ng/mL SCF, 3 U/mL EPO, 0.4 µg/mL dexamethasone (OUH pharmacy), 2mM L-Glutamine (Gibco, Cat No 25030081), 1x P/S, and 2 µg/mL doxycycline (Sigma-Aldrich, Cat No D9891). Cultures were maintained at 37°C 5% CO₂ incubator, with a cell density of 0.5-1 x 10⁶ cells/mL. The media was replaced every two days to ensure an effective doxycycline concentration.

Differentiation of HUDEP-2 cells used a two-phase liquid culture system, requiring a base media consisted of IMDM supplemented with 3% Human AB plasma, 10 µg/mL human insulin, 3 U/mL heparin, 3 U/mL EPO, 200 µg/mL holo-transferrin, 2% (v/v) FBS and 1x P/S. From day 0 to day 6, 1 ng/mL IL3, 50 ng/mL SCF, and 2 µg/mL doxycycline were added to the base media for cell differentiation. After 6 days, media was changed to the second phase, where only 300 µg/mL holo-transferrin was supplemented to the base media. Media was changed every two days. Cell density was maintained at 1 x 10⁶ cells/mL prior to day 6 and at 1.5 x 10⁶ cells/mL thereafter.

Generation of ATRX degron cell line

A guide RNA targeting the ATRX C-terminal domain (CTD) (gRNA sequence in Supplementary Table 1) were designed and cloned into the pX458-Ruby plasmid (Addgene 110164). A DNA donor template for homologous-directed recombination (HDR) was constructed to contain EGFP-FKBP12 F36V, flanked by 800 bp homologous arms on each side, directly linking to the absolute CTD of ATRX. The donor DNA was synthesised and inserted into pMK-RQ plasmid. To prevent cleavage of the donor DNA, all sgRNAs target sites within the donor plasmid were point-mutated without altering the encoded amino acids. For nucleofection, 2.5 µg of the pX458-Ruby-gRNA plasmid and 2.5 µg of the donor plasmid were co-transfected into 2×10^6 HUDEP-2 WT cells using the 2B Amaxa Human CD34 Cell Nucleofector Kit (Lonza, Cat No VPA-1003) on the AMAXA Nucleofector 2B system following the manufacturer's instructions. The transfected cells were cultured in HUDEP-2 SFEM expansion media supplemented with 0.75 µM RAD51-stimulatory compound-1 (RS-1) to enhance HDR efficiency. Two days post-transfection, Ruby+ cells were bulk sorted to recovering for 1 week and subsequently single-cell sorted into Terasaki plates (Nunc, Cat No 163118) for clonal screening. Successful grown clones were genotyped using the primers listed in Supplementary Table 1.

Generation of ATRX degon- $\psi\zeta$ VNTR KO cell line

The $\psi\zeta$ VNTR region was knocked out in the ATRX degon cell line using a dual-gRNA CRISPR-Cas9-mediated knockout strategy. Due to the high homology between *HBZ* and its pseudogene *HBZP1* where $\psi\zeta$ VNTR resides, the 5' sgRNA was designed to target *HBZP1* promoter where the sequences have no homology with *HBZ*, while the 3' sgRNA targeted a downstream region of *HBZP1*. This design facilitated the deletion of the entire *HBZP1* (~2.5 kb). The dual gRNAs were cloned into the pX458-eGFP (Addgene 48138) and pX458-Ruby (Addgene 110164) plasmids respectively, and 2.5 µg of each was co-transfected into 2×10^6 ATRX degon cells using the same nucleofection protocol as described above. Cells were cultured in SFEM expansion media after transfection, and GFP+ Ruby+ double-positive cells were sorted prior to single clonal screening via a PCR-based strategy. The gRNA and primer sequences used are provided in Supplementary Table 1.

RNA extraction and qPCR

0.5-2 x 10⁶ cells were collected in 350 µL RLT buffer (from QIAGEN RNeasy Mini Kit), snapped frozen on dry ice and stored at -80°C until use. Total RNA was purified using RNeasy mini kit (QIAGEN, Cat No 74104), and 1 µg of total RNA was used to generate complementary DNA (cDNA) using SuperScript III First Strand Synthesis SuperMix (ThermoFisher, Cat No 11752-250). All quantitative reverse transcription PCR (qRT-PCR) were carried out using inventoried TaqMan assays (Applied Biosystems; TaqMan IDs: HBA2/HBA1-Hs00361191_g1, HBB-Hs00747223_g1, HBG-Hs00361131_g1, HBM-Hs01392876_g1, NME4-Hs00359037_m1, RPL13A-Hs03043885_g1, RPS18-Hs01375212_g1, ACTB-Hs01060665_g1, GAPDH-Hs02758991_g1) and Taqman Universal PCR Master Mix II (ThermoFisher, Cat No 4440040) in technical triplicate on StepOne Plus Real-Time PCR System (Applied Biosystems). Data were first analysed using the delta-delta CT ($\Delta\Delta CT$) method and then normalised to the control sample. For PCR amplification of pseudo-zeta gene *HBZP1*, cDNA from HUDEP-2 WT cells was used as template and primers targeting zeta gene *HBZ* and pseudo-zeta gene *HBZP1* (listed in Supplementary Table 1) were used to distinguish the specific amplification of *HBZP1*. The PCR reaction was carried out using PWO polymerase (Roche, Cat No 11644947001) and Platinum Taq (Invitrogen, Cat No 10966018), with the addition of Applied Biotechnologies Buffer IV (1x), 20 mM MgCl₂, and a high G/C enhancer (1x, New England Biolabs, Cat No B9028) to overcome the high GC content and repetitive nature of the template. The thermal cycling conditions were as follows: 94°C for 2 min, 35 cycles of 94°C for 1 min, 60°C for 30 s, 72°C for 1 min 30 s and 72°C for 10 min.

Immunofluorescence staining

Cells were seeded on Cell-Tak (Corning, Cat No 354240)-coated CellView slides (Greiner Bio-One, Cat. No. 543978), and then fixed with 4% paraformaldehyde for 10 minutes, permeabilised with 0.1% Triton X-100 for 5 minutes, and blocked with 1% bovine serum albumin + 2% goat serum for 1 hour at room temperature. Cells were next incubated overnight at 4°C with an anti-γH2AX antibody (Merck, Cat. No. 05-636, use at 1:400) or anti-ubiquityl-histone H2A antibody (Cell Signaling Technology, Cat. No. 8240, use at 1:800). The following day, cells were incubated with Alexa Fluor 647-conjugated

secondary antibodies for 1 hour at room temperature, followed by staining with DAPI. Fluorescence images were acquired using a Leica DMI8 Thunder microscope and analysed in Fiji software.

Protein extraction and western blot

At least 1×10^6 cells were lysed in 50-200 μ L of RIPA buffer (Sigma, Cat No R0278) supplemented with digitonin (ThermoFisher, Cat No BN2006), Benzoylase (Merck, Cat No 71205-3), and protease inhibitor cocktail (Roche, Cat No 11836153001), based on the cell number. Cells lysis was conducted for 40-60 minutes at 4°C on an end-to-end rotator. The lysate was centrifuged at 16,000 g for 10 min at 4°C. Supernatant was collected and mixed with an equal volume of 2x Laemmli Sample Buffer (Bio-Rad, Cat No 1610737) containing 1/4 volume of 1M DTT (ThermoFisher, Cat No R0861).

Protein samples were denatured at 95°C for 5 minutes, chilled on ice, and loaded onto a NuPAGE Bis-Tris gel (ThermoFisher Scientific) using a Mini-PROTEAN system (Bio-Rad). Proteins were then transferred to a PVDF blotting membrane (Merck, Cat No 03010040001) overnight (14-18 hours) with constant 25 mA current, followed by blocking with 5% skimmed milk (Merck, Cat No 70166) dissolved in TBS-T (Tris buffered saline + 0.1% Tween-20). The membrane was incubated with primary antibodies for 1 hour at room temperature in 2.5% skimmed milk, washed three times with TBS-T, and then incubated with secondary antibodies for 1 hour at room temperature. After three additional washes, the membrane was exposed on X-ray film. Antibodies used in this study include: anti-ATRX (homemade mouse antibody, clone 39f; and Abcam, Cat No ab97508, use at 1:1000), anti-alpha tubulin (Abcam, mouse monoclonal, ab7291, use at 1:20,000), and HRP-conjugated secondary antibodies Goat anti-mouse IgG (ThermoFisher, Cat No 31430).

Smart-seq2 single cell RNA sequencing

CD34+ differentiated day 13 erythroid cells were stained with the viability dye Hoechst 33342 (ThermoFisher, Cat No 62249) before cell sorting. Single live nucleated cells were sorted into each well of a cold 384-well PCR plate (FrameStar 4titude, Cat No 4ti-0384/C)

containing 2 μ L of lysis buffer with barcoded Oligo(dT)⁶⁵ (0.2% Triton X-100 (Sigma), 2 U/ μ l of RNase inhibitor (TaKara, Cat No 2313A), 2.5 mM dNTP, 0.025 AU/mL protease, and ERCC RNA spike-in)⁶⁵ using a Sony SH800S Cell Sorter. Next, retrotranscription and PCR steps were performed⁶⁵. Briefly, proteinase in the lysis buffer was heat-inactivated at 72°C for 15 min, during which retrotranscription mix was prepared by mixing SMARTScribe retrotranscriptase (Clontech, Cat No 639537), RNase inhibitor, and template-switching oligo TSO-LNA (sequence: AAGCAGTGGTATCAACGCAGAGTACATrGrG+G, RNase-free HPLC purified). The RT mix was dispensed into each well after heat inactivation and first-strand cDNA was synthesised. Afterwards, the cDNA was amplified by SeqAMP (Clontech, Cat No 638509) using 21 PCR cycles. Amplified products from each plate were pooled, bead-purified, tagmented, and indexed using Tn5 enzyme (Illumina Nextera XT Kit, Cat No FC-131-1096) to construct libraries. The libraries were purified with AMPure beads, assessed on TapeStation System (Agilent), quantified using the NEBNext Library Quant Kit (NEB, Cat No E7630L), and sequenced on a NextSeq platform with 75 bp single-end reads using the NextSeq 500/550 High-output 75 Cycle Kit (Illumina, Cat No 20024906).

scRNA-seq data analysis

Demultiplexed FASTQ files were trimmed for polyA tails using TrimGalore; files from different lanes were merged using samtools and aligned to hg19 genome using STAR. Gene counts for each cell were obtained with FeatureCounts and normalised by dividing total library size of the cell and multiplying by the mean library size across all processed cells. Genes with normalised counts <1 were considered non-detected and their expression values were set to 0. The normalized counts were further applied with log₂ normalisation. QC filtering was performed to retain cells with >3000 reads; <10% mitochondrial reads, and >70% mapped reads per cell. Highly variable genes were identified by fitting a LOESS model of log₂(mean expression) versus coefficient of variation for each gene. Genes with a coefficient of variation above the fitted model and log₂(mean expression) ≥ 0 were selected as HVGs. Dimensionality reduction was performed by PCA (20 dimensions) and t-SNE ('Rtsne' package, with "perplexity = 10, max_iter = 500") using HVGs, and plotted using "ggplot2" package in R. Differentially

expressed genes were identified using a non-parametric Wilcoxon test and expressing cell frequency was computed using Fisher's exact tests on log₂-normalized counts for genes expressed in ≥ 5 cells. Significant genes were defined by an adjusted p value (false discovery rate (FDR) < 0.05) and an absolute log₂ fold change ($|\log_2\text{FC}| > 0.5$). P values were combined using Fisher's method, and adjusted p-values were calculated using the Benjamini & Hochberg FDR procedure. Violin plots from selected genes were generated using "ggplot2" package in R. GO analysis was conducted using ClusterProfiler R package. Differentially expressed gene set was compared with the gene list from org.Hs.eg.db from the Bioconductor package for GO analysis with settings ont = "BP", pAdjustMethod = "fdr". For cell cycle analysis, a Seurat object was created using the original count table. Cell cycle scores were computed and used to assign cell cycle stages. Fisher's test was used to examine cell cycle difference between groups.

Chromatin Immunoprecipitation sequencing (ChIP-seq) and data analysis

ATRX ChIP was performed on 5×10^7 cells using the ChIP Assay Kit (Millipore, Cat No 17-295) following an optimised protocol^{20,45}. Briefly, cells were double-fixed with firstly 2mM ethylene glycol bis succinimidyl succinate (EGS, Sigma, Cat No E3257) for 45 min and then 1% formaldehyde solution for 20 min at room temperature. The cross-linking was quenched with 125 mM glycine (Sigma-Aldrich, Cat No G7126). After cells lysis, the chromatin was fragmented using Covaris ME220 ultrasonicator (Peak Incident Power (PIP): 75, Duty factor (DF): 14, Cycles/burst (cpb): 1000, Duration: 900s, Temp: 6°C), followed by pre-clearing with Protein A/G Dynabeads (Invitrogen, Cat No 10001D, 10003D) before immunoprecipitation with 15 μg ATRX antibody (Abcam, Cat No ab97508). After sequential washes at 4°C, samples were eluted, de-crosslinked and proteinase K treated. DNA was precipitated using phenol/chloroform extraction and ethanol precipitation with GlycoBlue (15 mg/mL) (Thermo Scientific, Cat No AM9516) prior to dissolving in 20 μL of ultrapure water. DNA was quantified using the Qubit dsDNA HS assay (Invitrogen, Cat No Q32854) and indexed using NEBNext Ultra II DNA library prep kit (NEB, Cat No E7645L). Libraries were quantified, and sequenced on an Illumina NextSeq machine with paired-end reads.

ChIP-seq data quality was assessed by FASTQC. Data was analysed using a customised in-house pipeline (<https://github.com/Hughes-Genome-Group/NGseqBasic/releases>). Paired-end reads were aligned to the hg19 genome using bowtie 2. Output BAM files were sorted and indexed using Samtools, normalised to RPKM using Deeptools (--normalizeUsingRPKM), and converted to BigWig files for visualisation in the USCS genome browser. BigWig files were used for peak calling on LanceOtron (<https://lanceotron.molbiol.ox.ac.uk/>).

CRISPR/Cas9-induced DNA damage assay

2×10^6 of ATRX degron-VNTR KO differentiated day 6 cells were transfected with RNPs using the 2B Amaxa Human CD34 Cell Nucleofactor Kit on the AMAXA Nucleofactor 2B system. Following electroporation, cells were cultured in HUDEP-2 day 6 differentiation media for 2 days before being harvested for qPCR analysis. Three different sgRNAs were tested individually, and their sequences are provided in Supplementary Table 1.

DRIP-qPCR

The DRIP protocol was performed as previously described.⁶⁶ 1×10^8 cells were harvested followed by nuclear lysis. Nuclear extracts were incubated with 30 mg proteinase K at 37°C overnight, followed by DNA isolation. To minimize nonspecific RNA signals detected by the S9.6 antibody, nuclei were pre-treated with RNase I at 2 U per 100 µg for 15 minutes at 37°C and sonicated to 200-300 bp. Half the fragments were treated with RNase H (Roche) at 10 U per 100 µg overnight at 37°C. Treated and untreated samples underwent S9.6 antibody immunoprecipitation and enrichment using sheep anti-mouse IgG Dynabeads (ThermoFisher Scientific, Cat No 11031). Hybrids were extracted with phenol/chloroform, precipitated with glycogen, and resuspended in nuclease-free water. qPCR analysis was performed on the samples to detect enrichment around $\psi\zeta$ VNTR and a distal region on chromosome 16. The qPCR run was done using SYBR Green master mix with primers listed in Supplementary Table 1.

Dot blot analysis of R-loops

Briefly, nuclear DNA were extracted from ATRX degron cells (treated with dTAG-13-neg or dTAG-13) by potassium acetate and ethanol precipitated. Precipitated DNA was gently spooled and washed with 70% ethanol without centrifugation. DNA was allowed to air dry before resuspended in water followed by brief sonication to reduce DNA viscosity. DNA concentration was measured and adjusted to 400 ng/ μ l, followed by serial dilutions. For RNase H controls, an aliquot of DNA was incubated with 5 U RNase H (M0297S New England Biolabs) in 0.5M NaCl (EN0531 Thermo Scientific) at 37 °C for 20 min respectively, then serially diluted. Two microliters of each dilution were spotted on a Hybond-N+ nylon transfer membrane (RPN203B Amersham), air-dried and UV-crosslinked. The membrane was then blocked with 5% milk overnight, followed by a 2h incubation with anti-R-loop antibody S9.6 at 4 °C before washing, and then incubated with HRP-conjugated secondary antibody. Signals were detected using enhanced chemiluminescence (ECL) kit (P90720 Millipore).

RNase H overexpression assay

Three million of differentiation day 6 ATRX degron cells (with dTAG-13-neg or dTAG-13 treatment) were electroporated with 3 μ g of either a plasmid expressing GFP-tagged RNase H1 or a GFP alone control plasmid using Lonza Human CD34+ Cell Nucleofector Kit (Cat No VPA-1003) on the AMAXA Nucleofector 2B system. GFP+ cells were sorted after 12h for RNA extraction using RNeasy micro kit (QIAGEN, Cat No 74004), followed by qRT-PCR analysis.

Statistical analysis

Statistical analyses between two groups were conducted using a two-tailed unpaired Welch's t-test for normally distributed data, or the Mann-Whitney U-test for non-normally distributed data. Comparisons among three or more groups were performed using one-way ANOVA followed by Dunnett test. For datasets involving multiple conditions across groups, two-way ANOVA followed by Šídák's test was applied. For all the fold-change data, relative fold-change values were \log_2 -transformed before statistical analysis. Statistical significance was defined as $p < 0.05$, with significance levels represented as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. The number of independent

experiments was indicated in each figure. Detailed descriptions of the statistical tests used for each dataset, along with exact p -values, are provided in the corresponding figure legends.

Data Availability

The scRNA-seq and ChIP-seq data generated in this study have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) under accession codes GSE291201 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291201] and GSE291197 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291197] respectively. Source data are provided with this paper.

Code Availability

The in-house pipeline used for processing and aligning ChIP-seq data is available at GitHub (<https://github.com/Hughes-Genome-Group/NGseqBasic/releases>).

References

1. Gibbons, R. J., Picketts, D. J., Villard, L. & Higgs, D. R. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with α -thalassemia (ATR-X syndrome). *Cell* 80, 837–845 (1995).
2. Gibbons, R. Alpha thalassaemia-mental retardation, X linked. *Orphanet J Rare Dis* 1, 15 (2006).
3. Jiao, Y. *et al.* DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science (1979)* 331, 1199–1203 (2011).
4. Schwartzenuber, J. *et al.* Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* 2012 482:7384 482, 226–231 (2012).
5. Chen, X. *et al.* Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. *Cell Rep* 7, 104–112 (2014).
6. Xue, Y. *et al.* The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. *Proc Natl Acad Sci U S A* 100, 10635–10640 (2003).
7. Lewis, P. W., Elsaesser, S. J., Noh, K. M., Stadler, S. C. & Allis, C. D. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. *Proc Natl Acad Sci U S A* 107, 14075–14080 (2010).
8. Pladevall-Morera, D. *et al.* Proteomic characterization of chromosomal common fragile site (CFS)-associated proteins uncovers ATRX as a regulator of CFS stability. *Nucleic Acids Res* 47, 8004–8018 (2019).
9. Wong, L. H. *et al.* ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. *Genome Res* 20, 351–360 (2010).
10. Clynes, D. *et al.* ATRX dysfunction induces replication defects in primary mouse cells. *PLoS One* 9, (2014).
11. Conte, D. *et al.* Loss of Atrx Sensitizes Cells to DNA Damaging Agents through p53-Mediated Death Pathways. *PLoS One* 7, e52167 (2012).
12. Raghunandan, M. *et al.* Functional cross talk between the Fanconi anemia and ATRX/DAXX histone chaperone pathways promotes replication fork recovery. *Hum Mol Genet* 29, 1083–1095 (2020).
13. Juhász, S., Elbakry, A., Mathes, A. & Löbrich, M. ATRX Promotes DNA Repair Synthesis and Sister Chromatid Exchange during Homologous Recombination. *Mol Cell* 71, 11-24.e7 (2018).
14. Leung, J. W.-C. *et al.* Alpha thalassemia/mental retardation syndrome X-linked gene product ATRX is required for proper replication restart and cellular resistance to replication stress. *J Biol Chem* 288, 6342–6350 (2013).
15. Huh, M. S. *et al.* Stalled replication forks within heterochromatin require ATRX for protection. *Cell Death & Disease* 2016 7:5 7, e2220–e2220 (2016).
16. Elbakry, A., Juhász, S., Chan, K. C. & Löbrich, M. ATRX and RECQ5 define distinct homologous recombination subpathways. *Proc Natl Acad Sci U S A* 118, (2021).
17. Garbarino, J., Eckroate, J., Sundaram, R. K., Jensen, R. B. & Bindra, R. S. Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. *Transl Oncol* 14, (2021).

18. McDowell, T. L. *et al.* Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes. *Proc Natl Acad Sci U S A* 96, 13983–13988 (1999).
19. Law, M. J. *et al.* ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. *Cell* 143, 367–378 (2010).
20. Truch, J. *et al.* The chromatin remodeller ATRX facilitates diverse nuclear processes, in a stochastic manner, in both heterochromatin and euchromatin. *Nature Communications* 2022 13:1 13, 1–16 (2022).
21. Danussi, C. *et al.* Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. *Nature Communications* 2018 9:1 9, 1–15 (2018).
22. Qin, T. *et al.* ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. *Cell Rep* 38, (2022).
23. Ekwattanakit, S. *et al.* Analysis of DNA Methylation at the Human Alpha Globin Cluster during Hematopoiesis. *Blood* 112, 1861 (2008).
24. Bird, A. P., Taggart, M. H., Nicholls, R. D. & Higgs, D. R. Non-methylated CpG-rich islands at the human alpha-globin locus: implications for evolution of the alpha-globin pseudogene. *EMBO J* 6, 999 (1987).
25. Scott, C. *et al.* Recapitulation of erythropoiesis in congenital dyserythropoietic anemia type I (CDA-I) identifies defects in differentiation and nucleolar abnormalities. *Haematologica* 106, 2960–2970 (2020).
26. Kelliher, J., Ghosal, G. & Leung, J. W. C. New answers to the old RIDDLE: RNF168 and the DNA damage response pathway. *FEBS J* 289, 2467–2480 (2022).
27. Barbour, H., Daou, S., Hendzel, M. & Affar, E. B. Polycomb group-mediated histone H2A monoubiquitination in epigenome regulation and nuclear processes. *Nature Communications* vol. 11 Preprint at <https://doi.org/10.1038/s41467-020-19722-9> (2020).
28. Sobhian, B. *et al.* RAP80 Targets BRCA1 to Specific Ubiquitin Structures at DNA Damage Sites. *Science* (1979) 316, 1198–1202 (2007).
29. Li, Y. *et al.* Effect of ATRX and G-Quadruplex Formation by the VNTR Sequence on α -Globin Gene Expression. *ChemBiochem* 17, 928–935 (2016).
30. Tillotson, R. *et al.* A new mouse model of ATR-X syndrome carrying a common patient mutation exhibits neurological and morphological defects. *Hum Mol Genet* 32, 2485–2501 (2023).
31. Nguyen, D. T. *et al.* The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats. *EMBO Rep* 18, 914–928 (2017).
32. Bedrat, A., Lacroix, L. & Mergny, J. L. Re-evaluation of G-quadruplex propensity with G4Hunter. *Nucleic Acids Res* 44, 1746–1759 (2016).
33. Brázda, V. *et al.* G4Hunter web application: a web server for G-quadruplex prediction. *Bioinformatics* 35, 3493–3495 (2019).
34. Yan, Q. *et al.* Proximity labeling identifies a repertoire of site-specific R-loop modulators. *Nature Communications* 2022 13:1 13, 1–17 (2022).
35. Teng, Y. C. *et al.* ATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress. *Nature Communications* 2021 12:1 12, 1–14 (2021).

36. Crossley, M. P., Bocek, M. & Cimprich, K. A. R-Loops as Cellular Regulators and Genomic Threats. *Mol Cell* 73, 398–411 (2019).
37. Jalan, M. *et al.* RAD52 resolves transcription-replication conflicts to mitigate R-loop induced genome instability. *Nat Commun* 15, (2024).
38. Iannelli, F. *et al.* A damaged genome's transcriptional landscape through multilayered expression profiling around in situ-mapped DNA double-strand breaks. *Nature Communications* 2017 8:1 8, 1–12 (2017).
39. Shanbhag, N. M., Rafalska-Metcalf, I. U., Balane-Bolivar, C., Janicki, S. M. & Greenberg, R. A. ATM-Dependent chromatin changes silence transcription in cis to DNA double-strand breaks. *Cell* 141, 970–981 (2010).
40. Min, S., Ji, J. H., Heo, Y. & Cho, H. Transcriptional regulation and chromatin dynamics at DNA double-strand breaks. *Experimental & Molecular Medicine* 2022 54:10 54, 1705–1712 (2022).
41. Akter, J. *et al.* Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma. *Oncogenesis* 10, (2021).
42. Wang, Y. *et al.* G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. *Nat Commun* 10, 1–14 (2019).
43. Levy, M. A., Kernohan, K. D., Jiang, Y. & Bérubé, N. G. ATRX promotes gene expression by facilitating transcriptional elongation through guanine-rich coding regions. *Hum Mol Genet* 24, 1824–1835 (2015).
44. Proudfoot, N. J., Gil Sir William, A. & Maniatis, T. *The Structure of the Human Zeta-Globin Gene and a Closely Linked, Nearly Identical Pseudogene.* *Cell* vol. 31 (1982).
45. Truch, J., Telenius, J., Higgs, D. R. & Gibbons, R. J. How to Tackle Challenging ChIP-Seq, with Long-Range Cross-Linking, Using ATRX as an Example. *Methods Mol Biol* 1832, 105–130 (2018).
46. Lee, W. T. C. *et al.* Single-molecule imaging reveals replication fork coupled formation of G-quadruplex structures hinders local replication stress signaling. *Nature Communications* 2021 12:1 12, 1–14 (2021).
47. Duquette, M. L., Handa, P., Vincent, J. A., Taylor, A. F. & Maizels, N. Intracellular transcription of G-rich DNAs induces formation of G-loops, novel structures containing G4 DNA. *Genes Dev* 18, 1618–1629 (2004).
48. Girasol, M. J. *et al.* RAD51-mediated R-loop formation acts to repair transcription-associated DNA breaks driving antigenic variation in *Trypanosoma brucei*. *Proceedings of the National Academy of Sciences* 120, e2309306120 (2023).
49. Ngo, G. H. P., Grimstead, J. W. & Baird, D. M. UPF1 promotes the formation of R loops to stimulate DNA double-strand break repair. <https://doi.org/10.1038/s41467-021-24201-w> doi:10.1038/s41467-021-24201-w.
50. Watson, L. A. *et al.* Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span. *J Clin Invest* 123, 2049–2063 (2013).
51. Huh, M. S. *et al.* Compromised genomic integrity impedes muscle growth after Atrx inactivation. *J Clin Invest* 122, 4412 (2012).
52. Maréchal, A. & Zou, L. DNA Damage Sensing by the ATM and ATR Kinases. *Cold Spring Harb Perspect Biol* 5, (2013).

53. Masud, T. *et al.* Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461. *Scientific Reports* 2021 11:1 11, 1–20 (2021).
54. Rong, G., Pan, Z., Ding, M. & Wang, L. RNF168 suppresses the cancer stem cell-like traits of nonsmall cell lung cancer cells by mediating RhoC ubiquitination. *Environ Toxicol* 37, 603–611 (2022).
55. Xu, C., Xu, Y., Gursoy-Yuzugullu, O. & Price, B. D. The histone variant macroH2A1.1 is recruited to DSBs through a mechanism involving PARP1. *FEBS Lett* 586, 3920–3925 (2012).
56. Khurana, S. *et al.* A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance. *Cell Rep* 8, 1049–1062 (2014).
57. Kim, J. *et al.* Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions. *Mol Cell* 69, 36–47.e7 (2018).
58. Kim, J. *et al.* The macroH2A1.2 histone variant links ATRX loss to alternative telomere lengthening. *Nat Struct Mol Biol* 26, 213–219 (2019).
59. Ratnakumar, K. *et al.* ATRX-mediated chromatin association of histone variant macroH2A1 regulates α -globin expression. *Genes Dev* 26, 433–438 (2012).
60. Oberdoerffer, P. & Miller, K. M. Histone H2A variants: Diversifying chromatin to ensure genome integrity. *Semin Cell Dev Biol* 135, 59–72 (2023).
61. Mendoza, O., Bourdoncle, A., Boulé, J. B., Brosh, R. M. & Mergny, J. L. G-quadruplexes and helicases. *Nucleic Acids Res* 44, 1989 (2016).
62. Yu, Z. *et al.* DDX5 resolves R-loops at DNA double-strand breaks to promote DNA repair and avoid chromosomal deletions. *NAR Cancer* 2, (2020).
63. Lukas, C. *et al.* 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. *Nat Cell Biol* 13, 243–253 (2011).
64. Kurita, R. *et al.* Establishment of Immortalized Human Erythroid Progenitor Cell Lines Able to Produce Enucleated Red Blood Cells. *PLoS One* 8, (2013).
65. Rodriguez-Meira, A. *et al.* Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. *Mol Cell* 73, 1292–1305.e8 (2019).
66. Tan-Wong, S. M., Dhir, S. & Proudfoot, N. J. R-Loops Promote Antisense Transcription across the Mammalian Genome. *Mol Cell* 76, 600–616.e6 (2019).

Acknowledgements

Y.S., R.J.G. and D.R.H. were supported by the Chinese Academy of Medical Sciences Oxford Institute and CAMS Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002). R.J.G. received funding from Medical Research Council (UK) (grant number MC_UU_12025 / unit programme MC_UU_12009/3). We are very grateful to the WIMM Genome Engineering Facility (Dr. Philip Hublitz) for helping with the construction of the CRISPR plasmids used in this study. We would like to thank WIMM FACS facility and Single Cell facility for their support and guidance. We extend our gratitude to Ms. Gem Flint, Dr. Marco Di Antonio, Prof. Jim Hughes, Mr. Simone Riva, Dr. Ravza Gür, Dr. William Nathan, Dr. Andre Nussenzweig, and Dr. Antonio Rodríguez-Romera for their help and discussion.

Contributions

Y.S., R.J.G. and D.R.H. conceptualised the study and conceived the experimental design. Y.S. performed most of the experiments and formally analysed data. K.G. carried out cell culture, CRISPR-induced DNA damage assay, and pseudo-zeta cDNA PCR. S.M.T.-W. performed DRIP-qPCR and R-loops dot blot assay with supervision from N.J.P. Y.S. and S.W. performed the scRNA-seq analysis. C.A.F. designed pseudo-zeta cDNA PCR primers and performed the IEF assay. L.T. contributed to the 3D plotting of Biomark gene expression data. Y.S. and D.R.H. wrote the original manuscript; all authors read and approved the manuscript. R.J.G. and D.R.H. provided supervision and secured funding.

Conflicts of interest

Y.S. provides consultancy for Alethiomics Ltd, which had no involvement in the study's design, data collection, analysis, or manuscript preparation. All remaining authors declare no competing interests.

Figure legends

Fig. 1: Loss of ATRX selectively perturbs α -globin expression in a subset of cells.

a Schematic representation of human α -globin locus on chromosome 16p13.3. From the telomeric end, the locus contains the ζ -globin gene *HBZ*, the minor μ -globin gene *HBM*, the two α -globin genes *HBA2* and *HBA1*, and lastly the minor θ -globin gene *HBQ*. Two pseudogenes are present: $\psi\zeta$ *HBZP1* between *HBZ* and *HBM*, and $\psi\alpha1$ *HBAP1* between *HBM* and *HBA2*. Four distal enhancers (R1-R4) are situated upstream of the genes. **b** Schematic overview of the experimental workflow to generate *ATRX* knockout erythroid cells from healthy donor CD34⁺ HSPCs, followed by downstream analysis. **c** Western blot analysis of *ATRX* expression in day 7 differentiated cells, confirming efficient knockout. Quantification is presented on the right ($n = 3$ biological replicates, data shown as mean \pm SEM). $**p = 0.009$, two-tailed unpaired Welch's t-test. **d** Relative expression of *HBA*, *HBM* and α to β -like globin ratios by RT-qPCR analysis in day 10 and day 13 differentiated erythroid cells ($n = 3$ biological replicates, data shown as mean \pm SEM). Differences between AAVS1 and *ATRX* KO were compared using a two-tailed unpaired Welch's t-test on \log_2 -transformed fold-change values. **e** Genotyping summary of the collected 351 BFU-E colonies derived from *ATRX* KO samples showing genotype distribution. **f** Three-dimensional plot showing Biomark gene expression analysis of *ATRX*, *HBA* and *HBM* in single BFU-E colony. Each dot represents one colony, and the edited AAVS1 colonies are shown in blue; *ATRX* KO colonies with frameshift mutations are shown in red. AAVS1 controls gather around the internal space whereas the majority of the *ATRX* KO colonies assemble around the origin indicating low expression of *ATRX*, *HBM* and *HBA*. **g** Quantified gene expression analyses of BFU-E colonies show statistical differences between AAVS1 ($n = 15$) and *ATRX* KO groups ($n = 57$) (Mann-Whitney U test). Individual colonies are selected from two biological repeats. $***p = 1.493 \times 10^{-5}$ for *ATRX* expression, $**p = 0.003632$ for *HBM* expression, and $p = 0.9083$ for *HBA* expression. ns: not significant. Source data are provided as a Source Data file.

Fig. 2: scRNA-seq confirmed the stochastic effect of ATRX loss on gene expression and indicated an association with DNA damage response.

a t-SNE visualisation of scRNA-seq data showing individual cells in AAVS1 and ATRX KO samples using HVGs. **b** Volcano plot of differentially expressed genes in ATRX KO versus AAVS1 control. Each dot represents one gene. The horizontal dashed line indicates a significance threshold of 0.05, and the vertical dashed lines bound the minimal \log_2 fold-change (absolute value > 0.5) for the most-differentially-expressed genes. Upregulated genes are shown in red, downregulated genes in blue. The downregulated *HBM* is highlighted in blue and upregulated *RNF168* is highlighted in pink. **c** Violin plot of *RNF168* expression in both samples, with each dot representing a single cell. Percentages below sample labels show the number and proportion of *RNF168*-expressing cells. **d** Representative immunofluorescence images and quantification of γ H2AX foci in day 13 AAVS1 and ATRX KO samples. Scale bar = 10 μ m. 250 cells were randomly selected for quantification and lines show mean \pm SEM. A two-tailed Mann-Whitney U test was used for statistical analysis. * $p = 0.0111$ for number of foci per nucleus, **** $p < 0.0001$ for median intensity. **e** Expression of globin genes (*HBM*, *HBA*, *HBB*, *HBG*) in both samples. Red dashed frames highlight a subpopulation of ATRX KO cells with low *HBM* and *HBA* expression. **f** Single-cell expression of *HBB* and *HBM* in AAVS1 (top) and ATRX KO (bottom) samples, coloured by *HBM* expression level, showing a low-*HBM*/*HBA* subpopulation in ATRX KO sample. **g** Upregulated pathways in affected *HBM*^{low} cells by GO analysis, emphasising histone H2A ubiquitination. x-axis indicates p-value; dot size represents the number of DE genes attributed to each GO term; and dot colour indicates term abundance. **h** Representative immunofluorescence images and quantification of H2Aub intensity in day 13 AAVS1 and ATRX KO samples. Scale bar = 10 μ m. A total of 1000 cells were quantified, lines show mean \pm SEM (**** $p < 0.0001$, two-tailed Mann-Whitney U test). **i** Violin plot of *UIMC1* (*RAP80*) expression in ATRX KO *HBM*^{high}, *HBM*^{mid}, and the affected *HBM*^{low} cells. Source data are provided as a Source Data file.

Fig. 3: ATRX regulates gene expression at the α -globin locus via a G-rich VNTR.

a mRNA expression analysis of *HBM* by qRT-PCR during erythroid differentiation, normalized to *RPS18*, data are shown as mean \pm SEM (n = 3 biological replicates). **b** cDNA PCR amplification of the ζ -globin gene *HBZ* and its pseudogene *HBZP1* where the $\psi\zeta$ VNTR resides, in HUDEP-WT cells. The red arrows point the active and increasing

transcription of the pseudogene *HBZP1* during erythroid differentiation. **c** Representative ChIP-seq tracks showing ATRX occupancy at the $\psi\zeta$ VNTR-*HBM* locus across different stages of erythroid differentiation. The black blocks above peaks within each track show the peak call. **d** Schematic representation of the generation of the ATRX degron cell line. **e** ATRX expression in ATRX degron cells (left) and ATRX degron-VNTR KO cells (right) during erythroid differentiation, demonstrating dTAG-13-induced ATRX depletion. **f** Expression of *HBM* and *HBA* to β -like (*HBB+HBBG*) globin ratios on differentiation day 8 cells. ATRX + refers to ATRX degron cell treated with 100 nM of dTAG-13-Neg (a negative control compound for dTAG-13) from day 0 to day 8; ATRX - represents ATRX degron cell treated with 100 nM of dTAG-13 from day 0 to day 8; ATRX + / VNTR KO is ATRX degron- $\psi\zeta$ VNTR KO cell treated with dTAG-13-Neg from day 0 to day 8; ATRX - / VNTR KO is ATRX degron- $\psi\zeta$ VNTR KO cell treated with dTAG-13 from day 0 to day 8. Comparisons between two groups were performed using a two-tailed unpaired Welch's *t*-test on log₂-transformed fold-change values. Data are shown as mean \pm SEM (n = 5 biological replicates). ***p* = 0.0047 for *HBM* to β -like ratio between ATRX+ and ATRX- samples. Source data are provided as a Source Data file.

Fig. 4: G4s and R-loops formation at G-rich VNTRs, along with DNA damage, contributes to gene dysregulation.

a Expression of *HBM* and *HBA* to β -like (*HBB+HBBG*) globin in day 8 ATRX degron and ATRX degron-VNTR KO cells following 48h treatment with G4 stabiliser CX-5461. NT: untreated; dTAG-13: 100 nM from day 0 to day 8; CX-5461: 0.1 μ M from day 6 to day 8. Statistical analysis within each cell line used one-way ANOVA followed by Dunnett test on log₂-transformed values (n = 3 biological replicates, data shown as mean \pm SEM). For *HBM* to β -like ratio, **p* = 0.0267 (NT vs dTAG-13); ***p* = 0.0025 (NT vs CX-5461). **b** S9.6 dot-blot assay measuring global R-loops in dTAG-13-neg-treated ATRX+ and dTAG-13-treated ATRX- cells. RNase H served as a negative control. Quantification is shown as mean \pm SEM from three independent experiments. **p* = 0.0454 for 200 ng, two-way ANOVA Šídák's test. **c** DRIP-qPCR analysis showing increased R-loop levels around the VNTR region in ATRX-negative cells, but not at a distal region on chromosome 16 (n = 3 biological replicates, data shown as mean \pm SEM; **p* = 0.0422, two-way ANOVA Šídák's

test). **d** Expression of *HBM* to β -like globin following RNase H overexpression in ATRX-negative cells. (n = 3 biological replicates, data shown as mean \pm SEM; ***p* = 0.0084, one-way ANOVA Dunnett test). **e** Schematic of the $\psi\zeta$ VNTR locus and the sgRNA target sites used in the CRISPR/Cas9-induced DNA damage assay in VNTR KO cells. **f** Expression of *HBM* and *HBA* to β -like globin in day 8 ATRX degron-VNTR KO cells after 48h CRISPR assay (n = 3 biological replicates, data shown as mean \pm SEM). AAVS1 vs sgRNA used one-way ANOVA Dunnett test, and ATRX+ vs ATRX- used a two-tailed unpaired Welch's t-test. For *HBM* to β -like ratio, ***p* = 0.0067, 0.0013, 0.0013 for AAVS1 vs sgRNA-1, sgRNA-2, sgRNA-3 in VNTR KO-ATRAX+ cells; ***p* = 0.0058, 0.0053 for AAVS1 vs sgRNA-2, sgRNA-3 in VNTR KO-ATRAX- cells. **p* = 0.0332 for ATRX+ vs ATRX- cells. For *HBA* to β -like ratio, ***p* = 0.0057, 0.0022, 0.0026 for AAVS1 vs sgRNA-1, sgRNA-2, sgRNA-3 respectively in VNTR KO-ATRAX+ cells. Source data are provided as a Source Data file.


Fig. 5: Working model illustrating ATRX-mediated gene regulation at the human α -globin locus.


ATRX binds the G-rich $\psi\zeta$ VNTR region during transcription to facilitate proper gene expression. In the absence of ATRX, this G-rich region forms G4 structures and R-loops, which are prone to inducing DNA damage and thereby disrupting nearby gene expression *in cis*. The closest gene *HBM* is most strongly affected, followed by the more distal *HBA2/1* genes. Created in BioRender. Shen, Y. (2026) <https://BioRender.com/bq12e2p>.


Editorial Summary:


ATRX mutations are associated with developmental disorders and cancer, but how they affect gene regulation is unclear. Here, the authors report that ATRX loss can perturb alpha-globin gene expression by promoting G4- and R-loop-associated DNA damage via a G-rich repeat.



Peer review information: *Nature Communications* thanks Suming Huang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.









Wild-type cell:**ATRX-deficient cell:**